A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Summary

Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).

Timeline

Start

2024-01-11

Primary completion

2026-01-31

Completion

2027-02-28

Drugs

Indications